Genetic plasma cell signatures in high-risk smoldering myeloma versus multiple myeloma patients.

被引：0

作者：

Mailankody, Sham

Korde, Neha

Roschewski, Mark J.

Christofferson, Austin

Boateng, Martin

Zhang, Yong

Manasanch, Elisabet Esteve

Kazandjian, Dickran Gano

Kwok, Mary

Bhutani, Manisha

Tageja, Nishant

Zingone, Adriana

Costello, Rene

Lamy, Laurence

Hultcrantz, Malin

Papaemmanuil, Elli

Stetler-Stevenson, Maryalice

Figg, William Douglas

Keats, Jonathan J.

Landgren, Ola

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[2] NCI, Ctr Canc Res, Bethesda, MD 20892 USA

[3] Translat Genom Res Inst, Phoenix, AZ USA

[4] NCI, Bethesda, MD 20892 USA

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] US FDA, Off Hematol & Oncol Prod, Silver Spring, MD USA

[7] Walter Reed Natl Mil Med Ctr, Chevy Chase, MD USA

[8] Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Carolinas Healthcare Syst, Charlotte, NC USA

[9] NCI, NIH, Wheeling, WV USA

[10] NCI, Metab Branch, NIH, Bethesda, MD 20892 USA

[11] Paradigm Shift Therapeut, Bethesda, MD USA

[12] Sloan Kettering Inst, New York, NY USA

[13] NCI, Clin Pharmacol Program, NIH, Bethesda, MD 20892 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.8003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8003

引用

页数：2